To tackle the cancer specificity and immune-suppressive tumor microenvironment for CAR-T Cells therapy in solid tumors, DCB has developed Globo H/IO CAR-T cells targeting cancer-specific antigen of Globo H and secreting immune checkpoint blockade (ICB). The Globo H/IO CAR-T cells could selectively kill Globo H-positive cancer cells and effectively inhibit tumor growth. Therefore, the armored Globo H/IO CAR-T cells have clinical development potential application for treating Globo H-positive cancers.
Technical features:
・Targeting a tumor-associated antigen, Globo H
・Globo H CAR-T cells with novel secreted immune checkpoint inhibitors showed potent tumor inhibitory effect
・Treatment of Globo H-positive cancers
With over 400 dedicated researchers and state-of-the-art facilities , the Development Center for Biotechnology (DCB) specializes in developing biologics and small molecule drugs , botanical drugs , as well as technologies required for preclinical testing. Our expertise arises from the integration of a number of diverse disciplines , including biology , chemistry , protein purification and engineering , as well as analytical and quality assurance. Established in 1984 by Taiwan's Ministry of Economic Affairs (MOEA) , Department of Industrial Technology (DoIT) , DCB was initially tasked with establishing the biotechnology industry in Taiwan. Through strategic global alliances and technology transfer agreements , DCB has successfully fostered the development of a complete biotech infrastructure and value chain , as well as a diverse array of applications for use by the private sector. As a result , DCB has become one of Taiwan's most important research institutes. DCB's mission is to facilitate the ongoing growth and development Taiwan's biotechnology industry. To this end , we strive to act as the industry's partner , coordinating resources among government , academia and private companies. DCB remains a key force in building and upgrading Taiwan's biomedical infrastructure, developing key technologies , and growing Taiwan's professional workforce. Our ultimate aim is to improve the quality of life for the people of Taiwan and the world. To this end , DCB fosters international partnerships and collaborations with research institutes and global biopharmaceuticals throughout Asia and the world.
Name:
Phone:
Address:No.107, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City 11571, Taiwan, R.O.C.
Degradable Implantable Flexible Microelectrode Patch with High-Resolution Electrical Stimulation, Electrophysiological Signal Sensing, and Cellular Regenerative Therapy
A Site-Specific B7-H3 Targeting Antibody-Drug Conjugate for Cancer Therapy
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
DBPR22998:A Potent QPCTL (IsoQC) Inhibitor Targeting CD47-SIRP⍺ Axis for Cancer Immunotherapy
Technology maturity:Experiment stage
Exhibiting purpose:Technology transactions、Patent transactions、Product promotion、Display of scientific results
Trading preferences:Negotiate by self
Coming soon!